Literature DB >> 27519279

Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up of Procedure Efficiency.

Giuseppina Li Pira1, David Malaspina2, Elia Girolami2, Simone Biagini2, Elisabetta Cicchetti2, Gianpiero Conflitti2, Manuel Broglia2, Stefano Ceccarelli2, Stefania Lazzaro2, Daria Pagliara2, Antonella Meschini2, Alice Bertaina2, Mauro Montanari2, Franco Locatelli3.   

Abstract

HLA-haploidentical family donors represent a valuable option for children requiring allogeneic hematopoietic stem cell transplantation (HSCT). Because graft-versus-host diseases (GVHD) is a major complication of HLA-haploidentical HSCT because of alloreactive T cells in the graft, different methods have been used for ex vivo T cell depletion. Removal of donor αβ T cells, the subset responsible for GVHD, and of B cells, responsible for post-transplantation lymphoproliferative disorders, have been recently developed for HLA-haploidentical HSCT. This manipulation preserves, in addition to CD34+ progenitors, natural killer, γδ T, and monocytes/dendritic cells, contributing to anti-leukemia activity and protection against infections. We analyzed depletion efficiency and cell yield in 200 procedures performed in the last 3 years at our center. Donors underwent CD34+  hematopoietic stem cell (HSC) peripheral blood mobilization with granulocyte colony-stimulating factor (G-CSF). Poor CD34+ cell mobilizers (48 of 189, 25%) received plerixafor in addition to G-CSF. Aphereses containing a median of 52.5 × 109 nucleated cells and 494 × 106 CD34+ HSC were manipulated using the CliniMACS device. In comparison to the initial product, αβ T cell depletion produced a median 4.1-log reduction (range, 3.1 to 5.5) and B cell depletion led to a median 3.4-log reduction (range, 2.0 to 4.7). Graft products contained a median of 18.5 × 106 CD34+ HSC/kg recipient body weight, with median values of residual αβ T cells and B cells of 29 × 103/kg and 33 × 103/kg, respectively. Depletion efficiency monitored at 6-month intervals demonstrated steady performance, while improved recovery of CD34+ cells was observed after the first year (P = .0005). These data indicate that αβ T cell and B cell depletion of HSC grafts from HLA-haploidentical donors was efficient and reproducible.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Graft manipulation; HLA-haploidentical transplantation; αβ T cell depletion

Mesh:

Substances:

Year:  2016        PMID: 27519279     DOI: 10.1016/j.bbmt.2016.08.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

1.  Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts.

Authors:  Javid Gaziev; Antonella Isgrò; Pietro Sodani; Katia Paciaroni; Gioia De Angelis; Marco Marziali; Michela Ribersani; Cecilia Alfieri; Alessandro Lanti; Tiziana Galluccio; Gaspare Adorno; Marco Andreani
Journal:  Blood Adv       Date:  2018-02-13

2.  High proportions of CD3+ T cells in grafts delayed lymphocyte recovery and reduced overall survival in haploidentical peripheral blood stem cell transplantation.

Authors:  Ying Zhang; Caili Guo; Chunhong Sun; Ying Chen; Huachao Zhu; Jieying Xi; Mei Zhang; Pengcheng He; Xiaoning Wang
Journal:  Mol Clin Oncol       Date:  2020-04-02

Review 3.  TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data.

Authors:  Kieran Sahasrabudhe; Mario Otto; Peiman Hematti; Vaishalee Kenkre
Journal:  Leuk Lymphoma       Date:  2018-09-06

Review 4.  The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.

Authors:  Stefan O Ciurea; Monzr M Al Malki; Piyanuch Kongtim; Ephraim J Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Patrick Ben Soussan; Yolande Arnault; Rupert Handgretinger; Denis-Claude Roy; Paul V O'Donnell; Asad Bashey; Scott Solomon; Rizwan Romee; Jorge Gayoso; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2019-03-04       Impact factor: 5.483

5.  Depletion of αβ+ T and B Cells Using the CliniMACS Prodigy: Results of 10 Graft-Processing Procedures from Haploidentical Donors.

Authors:  Eva Haastrup; Marianne R S Ifversen; Carsten Heilmann; Anne Fischer-Nielsen
Journal:  Transfus Med Hemother       Date:  2019-03-07       Impact factor: 3.747

6.  HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia.

Authors:  Luisa Strocchio; Daria Pagliara; Mattia Algeri; Giuseppina Li Pira; Francesca Rossi; Valentina Bertaina; Giovanna Leone; Rita Maria Pinto; Marco Andreani; Emanuele Agolini; Katia Girardi; Stefania Gaspari; Lavinia Grapulin; Francesca Del Bufalo; Antonio Novelli; Pietro Merli; Franco Locatelli
Journal:  Blood Adv       Date:  2021-03-09

Review 7.  Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Franco Aversa; Lucia Prezioso; Ilenia Manfra; Federica Galaverna; Angelica Spolzino; Alessandro Monti
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-25       Impact factor: 2.576

Review 8.  Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.

Authors:  A Saad; L S Lamb
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 9.  When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Adam Lamble; Rachel Phelan; Michael Burke
Journal:  J Clin Med       Date:  2017-07-07       Impact factor: 4.241

10.  Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia.

Authors:  Marco Andreani; Manuela Testi; Pietro Sodani; Maria Troiano; Andrea Di Luzio; Giuseppe Testa; Michela Falco; Elvira Poggi; Javid Gaziev; Antonina Piazza
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-03-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.